Valuation: ORIC Pharmaceuticals, Inc.

Market Cap 1.12B 981M 906M 845M 1.59B 106B 1.62B 10.87B 4.22B 52.31B 4.21B 4.12B 182B P/E 2026 *
-7.43x
P/E 2027 * -6.73x
Enterprise Value 1.01B 886M 818M 763M 1.44B 95.66B 1.46B 9.81B 3.81B 47.21B 3.8B 3.72B 164B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.15%
Yield 2026 *
-
Yield 2027 * -
1 day+6.65%
1 week+21.55%
1 month+28.17%
3 months-14.52%
6 months+32.40%
Current year+32.40%
1 week 9.27
Extreme 9.27
10.92
1 month 7.32
Extreme 7.315
10.92
Current year 7.23
Extreme 7.23
14.25
1 year 7.23
Extreme 7.23
14.93
3 years 3.9
Extreme 3.8951
16.65
5 years 2.36
Extreme 2.36
26.7
10 years 2.36
Extreme 2.36
40.81
Manager TitleAgeSince
Chief Executive Officer 47 06/05/2018
Director of Finance/CFO 52 31/08/2019
Chief Tech/Sci/R&D Officer - 17/08/2025
Director TitleAgeSince
Chairman 68 06/03/2018
Director/Board Member 47 06/05/2018
Director/Board Member 62 31/01/2020
Date Insider Type Main position Quantity % Market Cap.
02-23Fiscal year

Chief Financial Officer

156,000 0.1602%
01-15Sell

Founder

6,700 0.0069%
01-01Free

Director

40,000 0.0411%
Change 5-day change 1-year change 3-year change Capi.($)
+6.65%+21.55%+6.70%+39.56% 1.05B
+3.31%-0.20%+72.71%+128.31% 55.78B
-1.32%+17.12%+79.02%+99.82% 55.66B
-1.28%+2.68%-12.60%-13.79% 23.84B
+1.79%+4.38%+5.94%+405.31% 22.7B
-1.93%+11.11%+34.89%-7.86% 18.5B
+4.45%+5.06%+36.50%-30.43% 16.12B
+0.24%+5.98%+23.45%+184.72% 13.64B
+0.14%+9.60%+33.31% - 12.95B
+1.83%+4.58%+77.42%+132.45% 12.16B
Average +1.39%+6.86%+35.73%+104.23% 23.24B
Weighted average by Cap. +0.82%+5.25%+48.29%+114.48%

Financials

2026 *2027 *
Net sales - -
Net income -156M -137M -126M -118M -222M -14.77B -226M -1.51B -588M -7.29B -587M -574M -25.4B -190M -166M -153M -143M -269M -17.93B -274M -1.84B -714M -8.85B -712M -697M -30.82B
Net Debt -109M -95.69M -88.33M -82.4M -155M -10.34B -158M -1.06B -411M -5.1B -411M -402M -17.77B -231M -202M -187M -174M -329M -21.87B -334M -2.24B -870M -10.79B -869M -850M -37.6B
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
104
Date Price Change Volume
30/06/26 US$10.83 +6.65% 1,663,131
29/06/26 US$10.16 +6.56% 1,123,898
26/06/26 US$9.530 +0.74% 3,762,524
25/06/26 US$9.460 +0.32% 1,646,575
24/06/26 US$9.430 +5.84% 1,707,947
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
10.83USD
Average target price
20.29USD
Spread / Average Target
+87.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ORIC Stock